Top Story

Six chemotherapy cycles failed to improve outcomes in node-negative breast cancer

December 18, 2014

SAN ANTONIO — Patients with node-negative breast cancer who received six cycles of 5-fluorouracil, epirubicin and cyclophosphamide experienced similar DFS and OS as patients who received four cycles of doxorubicin and cyclophosphamide, according to results of a phase 3 study presented at the San Antonio Breast Cancer Symposium.

“[In the MA-5 trial, the NCIC Clinical Trials Group] administered a dose-intensified epirubicin program, and the RFS and OS results were encouraging,” Charles Edward Geyer, Jr., MD, FACP, associate director for clinical research at Virginia Commonwealth University Massey Cancer Center, said during his presentation. “Additionally, the French Adjuvant Study Group around that time had also evaluated their standard adjuvant regimen of FEC-50 and had shown that six cycles of therapy were more effective than three. So, at that time, we had two separate trials looking at different epirubicin schedules, both of which had seemed to be positive. It seemed reasonable at that time to compare [doxorubicin and cyclophosphamide] with one of those regimens. Since we were going to conclude the study in node-negative patients and include post-menopausal women, we chose the FEC-100 [chemotherapy regimen] because of its improved toxicity profile.”

Jean M. Weigert, MD, FACR Meeting News Coverage

Ultrasound improved cancer detection in women with dense breasts

December 17, 2014
SAN ANTONIO — Women with dense breasts who underwent ultrasound had cancers detected that were missed during screening mammography, according to results of a…
Weekly paclitaxel or docetaxel every 3 weeks extended DFS in breast cancer Meeting News Coverage

Weekly paclitaxel or docetaxel every 3 weeks extended DFS in breast cancer

December 16, 2014
SAN ANTONIO — Women with axillary node-negative or high-risk node-negative breast cancer achieved prolonged DFS and marginally improved OS when they received…
Meeting News CoveragePerspective

Multigene test predicted DCIS recurrence risk after breast-conserving surgery

December 15, 2014
SAN ANTONIO — A 12-gene test accurately predicted the risk for recurrence of ductal carcinoma in situ among women who had undergone breast-conserving surgery, according…
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
WINS: Lower dietary fat intake reduced mortality in patients with early-stage breast cancer

WINS: Lower dietary fat intake reduced mortality in patients with early-stage breast cancer

December 12, 2014
SAN ANTONIO — Anees B. Chagpar, MD, MSc, MPH, MA, FRCS(C), FACS, director of the Breast Center at Smilow Cancer…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Six chemotherapy cycles failed to improve outcomes in node-negative breast cancer Meeting News Coverage

Six chemotherapy cycles failed to improve outcomes in node-negative breast cancer

December 18, 2014
SAN ANTONIO — Patients with node-negative breast cancer who received six cycles of 5-fluorouracil, epirubicin and cyclophosphamide experienced…
Jean M. Weigert, MD, FACR Meeting News Coverage

Ultrasound improved cancer detection in women with dense breasts

December 17, 2014
SAN ANTONIO — Women with dense breasts who underwent ultrasound had cancers detected that were missed during screening mammography, according to…
Weekly paclitaxel or docetaxel every 3 weeks extended DFS in breast cancer Meeting News Coverage

Weekly paclitaxel or docetaxel every 3 weeks extended DFS in breast cancer

December 16, 2014
SAN ANTONIO — Women with axillary node-negative or high-risk node-negative breast cancer achieved prolonged DFS and marginally improved OS when…
Meeting News CoveragePerspective

Multigene test predicted DCIS recurrence risk after breast-conserving surgery

December 15, 2014
SAN ANTONIO — A 12-gene test accurately predicted the risk for recurrence of ductal carcinoma in situ among women who had undergone breast-conserving…
Meeting News Coverage

Everolimus did not extend PFS in HER-2–positive breast cancer

December 15, 2014
SAN ANTONIO — The addition of the mTOR inhibitor everolimus to trastuzumab and paclitaxel failed to extend PFS in women with…
Meeting News Coverage

Reduced dietary fat intake extended survival in some women with breast cancer

December 13, 2014
SAN ANTONIO — Women with early-stage, hormone-unrelated breast cancer who reduced dietary fat intake for 5 years following diagnosis…
Elderly patients with early-stage breast cancer derived no survival benefit from capecitabine monotherapy Meeting News Coverage

Elderly patients with early-stage breast cancer derived no survival benefit from capecitabine monotherapy

December 13, 2014
SAN ANTONIO — Capecitabine monotherapy did not improve outcomes in elderly patients with moderate- to high-risk early-stage breast cancer…
Meeting News Coverage

Carboplatin improved outcomes in patients with BRCA1/2-mutated metastatic breast cancer

December 12, 2014
SAN ANTONIO — Patients with metastatic breast cancer who harbored BRCA1 or BRCA2 mutations achieved superior response rates and PFS when they…
IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer Meeting News CoverageVideo

IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

December 12, 2014
SAN ANTONIO — Erin W. Hofstatter, MD, director of the Breast Cancer Genetics and Prevention Program at Yale Cancer Center, discusses the…
Meeting News Coverage

Androgen-receptor blocking effective for breast cancer treatment

December 12, 2014
The effects of blocking androgen receptors in breast cancer were evaluated by three studies presented at the San Antonio Breast Cancer Symposium…
More Headlines »
morganatic-roan